DENVER, Colo. (247marketnews.com) — The following are showing notable momentum today, with Kraig Biocraft Laboratories (OTCQB:KBLB), Iovance Biotherapeutics (NASDAQ:IOVA), Volato Group (NYSEAMERICAN:SOAR), Carnival Corporation (NYSE:CCL), Teads Holding (NASDAQ:TEAD), Quantum-Si (NASDAQ:QSI), and KALA Bio (NASDAQ:KALA) all posting gains and holding their moves as traders look toward the afternoon and tomorrow.
Kraig Biocraft Laboratories
Kraig Labs (OTCQB:KBLB) is putting a major commercialization marker on the board after announcing the shipment of its first commercial order of recombinant spider silk yarn to a globally recognized performance sports brand. The custom-engineered yarn is being developed as part of a confidential pilot program for what Kraig describes as a first-of-its-kind performance textile. While the initial shipment is intentionally small, the significance is that Kraig’s material is moving beyond production demonstrations and into an actual customer-led product-development process.
CEO Kim Thompson called the delivery “a huge milestone for Kraig Labs,” emphasizing that high-performance sports represent a demanding environment in which advanced materials must demonstrate real-world performance. The company is increasingly focused on proving that recombinant spider silk can transition from an intriguing laboratory material into a commercially useful fiber with characteristics including strength, toughness, flexibility and low weight.
The latest development also arrives shortly after Kraig announced completion of its functional and living Atlas Gene Library, which the company says is designed to support development of new recombinant spider silks with potentially customized characteristics. That could eventually allow fibers to be tailored toward different commercial or industrial requirements.
Iovance Biotherapeutics
Iovance Biotherapeutics (NASDAQ:IOVA) delivered one of the day’s more direct fundamental catalysts after raising its full-year 2026 revenue guidance to $410 million-$420 million, up $55 million at the midpoint from its previous $350 million-$370 million range. The company attributed the increase to sustained U.S. demand for Amtagvi and Proleukin, with the midpoint of the new guidance implying nearly 60% year-over-year revenue growth.
The company’s commercial momentum is centered on Amtagvi (lifileucel), its tumor-infiltrating lymphocyte therapy for previously treated advanced melanoma. Iovance reported second-quarter 2026 total product revenue of $99.3 million and has expanded its authorized treatment-center network to approximately 100 locations, with a goal of reaching at least 110 by year-end.
Interim CEO Frederick Vogt said, “Increasing patient demand and our current manufacturing schedule provide strong visibility into our third and fourth quarter revenues.” Iovance is also advancing lifileucel into additional solid-tumor indications while working on next-generation TIL technologies.
Volato Group
Volato Group (NYSEAMERICAN:SOAR) has rapidly transformed its market narrative around artificial intelligence infrastructure, with its Alignment Engine subsidiary announcing approximately $1.17 billion in aggregate contract value from two four-year, take-or-pay orders with a large AI customer. The agreements represent Alignment Engine’s first major customer commitment for its AI infrastructure platform.
The orders call for dedicated, single-tenant AMD GPU infrastructure at Alignment Engine’s Ohio AI infrastructure campus. The first deployment is scheduled around AMD MI355X GPUs with a contractual start date of December 31, 2026, followed by a second deployment using AMD MI455X GPUs beginning June 30, 2027. The agreements include approximately $133 million in contractual prepayments, including approximately $40 million due following execution of the initial order.
CEO Chris Ensey called the announcement “a transformational commercial milestone for Alignment Engine,” while CFO Mark Heinen emphasized the importance of building infrastructure against long-term contracted demand and customer cash commitments.
Carnival Corporation
Carnival Corporation (NYSE: CCL) delivered another major market catalyst with third-quarter 2026 results showing record revenue, record net yields and record net income. The cruise giant reported $1.9 billion in net income, $2.0 billion in adjusted net income and $3.0 billion in adjusted EBITDA, while net yields in constant currency climbed 2.4%.
Perhaps more important for the forward-looking story, Carnival said bookings for 2027 are at record levels for both occupancy and pricing. Third-quarter customer deposits reached a record $7.6 billion, up approximately $500 million from the prior-year record despite flat capacity growth over the next 12 months.
CEO Josh Weinstein said, “Our booking trends continued to strengthen throughout the quarter,” pointing to volumes meaningfully ahead of the prior year. The company also expects more than $150 million of operational improvement in adjusted net income versus its June guidance.
Carnival has additionally repurchased approximately $1.2 billion of shares year-to-date, while fuel consumption per available lower berth day declined 3.8% year over year. The combination of record bookings, stronger yields, improving operating performance and capital returns gives CCL multiple catalysts for investors to monitor.
Teads Holding
Teads (NASDAQ:TEAD) is pushing deeper into the rapidly expanding retail-media market through a new global partnership with commerce-media platform Koddi. The agreement is designed to bring an open OpenRTB standard to onsite retail-media inventory across the United States and Europe, allowing advertisers to access Sponsored Product Ads and high-intent display placements through Teads Ad Manager across Koddi-powered networks.
The strategic opportunity is tied to one of advertising’s major structural challenges: fragmentation. Teads and Koddi cited IAB Europe research showing that fragmentation among retail-media networks and a lack of standardization remain significant obstacles for advertisers.
Justin Sparks, Teads’ GM of Retail & Commerce Media, said advertisers can activate retail media as part of broader omnichannel campaigns while retailers can gain access to additional demand. Koddi President Nicholas Ward described the integration as a milestone toward making retail media “truly programmatic on a global scale.”
Quantum-Si Incorporated
Quantum-Si Incorporated (NASDAQ:QSI) delivered a potentially significant technology catalyst with interim development data for its next-generation Proteus protein-sequencing platform. At the 2026 World HUPO Congress, the company presented results showing substantial performance improvements versus its commercially available Platinum Pro system, despite Proteus still being under development and not yet fully optimized.
The headline numbers are notable. In a control-peptide study, Proteus produced a median 30 times more alignments than Platinum Pro from a single chamber and achieved a 4.8-fold lower median false-discovery rate. In protein mixtures, Proteus identified 1.6 to 2.0 times more peptides, while a 24-protein panel showed detection of all 24 proteins compared with an average of 20.3 on Platinum Pro.
CEO Jeff Hawkins characterized the results as “a fundamentally superior platform technology, not simply a larger version of Platinum Pro.” The company said the system has not yet been fully optimized, meaning additional development work remains before commercialization.
KALA Bio
KALA Bio (NASDAQ:KALA) is making a major strategic move beyond its existing biotechnology platform with a proposed acquisition of a nationwide telehealth business. The company signed a non-binding letter of intent to acquire the privately held management-services organization supporting a provider-led telehealth platform serving all 50 states, in a transaction valued at approximately $15 million.
According to unaudited information supplied by the target’s management, the business generated approximately $12.7 million in trailing-12-month revenue through August 2026 and has generated more than $48 million in sales since its 2023 founding. The platform has reportedly served more than 90,000 clients and focuses on weight management, hormone health, longevity and sexual wellness.
KALA CEO and CFO Avi Minkowitz said, “This transaction would add an established, revenue-generating platform to KALA’s operating business,” while pointing to potential opportunities to introduce Virotek genetic testing and other preventative-care offerings through the telehealth platform. The company also plans to evaluate the target’s AI infrastructure for potential integration with its Researgency.ai strategy.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.